Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
5-Year IF – 2.0, IF – 1.9, JCI (2024) – 0.43
Scopus CiteScore – 4.3
Q1 in SJR 2024, SJR score – 0.598, H-index: 49 (SJR)
ICV – 161.00; MNiSW – 70 pts
Initial editorial assessment and first decision within 24 h

ISSN 1899–5276 (print), ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2014, vol. 23, nr 4, July-August, p. 559–565

Publication type: original article

Language: English

The Adjunctive Effect of Tenoxicam During Non-Surgical Periodontal Treatment on Clinical Parameters and Gingival Crevicular Fluid Levels of MMP-8 and TNF-α in Patients with Chronic Periodontitis – Randomized, Double-Blind Clinical Trial

Özgür Özgören1,A,B,C,D, Hakan Develioglu2,A,D,E,F, Güliz Güncü3,C, Abdullah Akman3,C, Ezel Berker3,A,B

1 Darıca Mouth and Tooth Health Center, Kocaeli, Turkey

2 Department of Periodontology, Faculty of Dentistry, Cumhuriyet University, Sivas, Turkey

3 Department of Periodontology, Faculty of Dentistry, Hacettepe University, Ankara, Turkey

Abstract

Background. Matrix metalloproteinases (MMPs) and cytokines play a role of extracellular matrix degradation and remodelling, and are significantly involved in the course of periodontal disease.
Objectives. The purpose of this study was to evaluate the adjunctive effect of administering an oxicam non-steroidal anti-inflammatory drug (NSAID), tenoxicam, during non-surgical (phase 1) periodontal treatment on clinical parameters and gingival crevicular fluid (GCF) levels of MMP-8 and TNF-α in subjects with chronic periodontitis.
Material and Methods. . A total of 32 subjects with chronic periodontitis were randomized into two groups: 1) phase I periodontal treatment + NSAID and 2) phase I periodontal treatment + placebo. Phase I periodontal therapy consisted of scaling and root planning (SPR), which was provided by a single therapist masked with respect to group assignment. Patients in group 1 received a systemic NSAID (20 mg tenoxicam tablet once daily for 10 days). Clinical measures and GCF samples were obtained immediately prior to periodontal treatment and 30 days afterwards from all subjects. Clinical measures included a plaque index, gingival index, gingival bleeding time index, probing depth, and clinical attachment level. The MMP-8 and TNF-α levels in the GCF were assayed using an enzyme-linked immunosorbent assay.
Results. . With the exception of clinical attachment level, all clinical measures showed a significant (p < 0.05) improvement following non-surgical treatment in both the NSAID and placebo groups. A significant decrease in MMP-8 levels (p < 0.05) was observed at post-treatment in the NSAID group but not in the placebo group (p > 0.05). Treatment exhibited no effect on TNF-α levels (p > 0.05). There was also no statistically significant difference in clinical measurements after treatment between the two groups (p > 0.05). Moreover, the post treatment MMP-8 level in group 1 was statistically significant higher than the placebo group (p < 0.05).
Conclusion. The adjunctive administration of tenoxicam during phase I periodontal treatment decreases MMP-8 levels in gingival crevicular fluid in patients with chronic periodontitis. But no benefits were observed.

Key words

MMP-8, TNF-α, chronic periodontitis, anti-inflammatory drug.

References (55)

  1. Kinane DF, Lappin DF: Clinical, pathological and immunulogical aspects of periodontal disease. Acta Odontol Scand 2001, 59, 154–160.
  2. Ingman T, Sorsa T, Michaelis J, Konttinen YT: Immunohistochemical study of neutrophil and fibroblast-type collagenases and stromelysin-1 in adult periodontitis. Scand J Dent Res 1994, 102, 342–349.
  3. Birkedal-Hansen H: Role of matrix metalloproteinases in human periodontal diseases. J Periodontol 1993, 64, 474–484.
  4. Reddy NR, Roopa D, Babu DS, Kumar PM, Raju CM, Kumar NS: Estimation of matrix metalloproteinase-3 levels in gingival crevicular fluid in periodontal disease, health and after scaling and root planing. J Indian Soc Periodontol 2012, 16, 549–552.
  5. Woolley DE, Davies RM: Immunolocalization of collagenase in periodontal tissues. J Periodontal Res 1981, 16, 292–297.
  6. Hernández Ríos M, Sorsa T, Obregón F, Tervahartiala T, Valenzuela MA, Pozo P, Dutzan N, Lesaffre E, Molas M, Gamonal J: Proteolytic roles of matrix metalloproteinase (MMP)-13 during progression of chronic periodontitis: initial evidence for MMP-13/MMP-9 activation cascade. J Clin Periodontol 2009, 36, 1011–1017.
  7. Sorsa T, Ding YL, Ingman T: Cellular source, activation and inhibition of dental plaque collagenase. J Clin Periodontol 1995, 22, 709–717.
  8. Sorsa T, Tjaderhane L, Salo T: Matrix metalloproteinases (MMPs) in oral diseases. Oral Dis 2004, 10, 311–318.
  9. Sorsa T, Uitto VJ, Suomolainen M, Vauhkonen M, Lindy S: Comparison of interstitial collagenases from human gingiva, sulcular fluid and polymorphonuclear leukocytes. J Periodontal Res 1988, 23, 386–393.
  10. Söder B, Airila Mansson S, Söder P-Ö, Kari K, Meurman J: Levels of matrix metalloproteinases-8 and -9 with simultaneous presence of periodontal pathogens in gingival crevicular fluid as well as matrix metalloproteinase-9 and cholesterol in blood. J Periodontal Res 2006, 41, 411–417.
  11. Buduneli N, Vardar S, Atilla G, Sorsa T, Luoto H, Baylas H: Gingival crevicular fluid matrix metalloproteinase-8 levels following adjunctive use of meloxicam and initial phase of periodontal therapy. J Periodontol 2002, 73, 103–109.
  12. Gangbar S, Overall CM, McCulloch CA, Sodek J: Identification of polymorphonuclear leukocyte collagenase and gelatinase activities in mouthrinse samples: correlation with periodontal disease activity in adult and juvenile periodontitis. J Periodontal Res 1990, 25, 257–267.
  13. Haerian A, Adonogianaki E, Money J, Manos A, Kinane DF: Effects of treatment on gingival crevicular collagenase, stromelysin and tissue inhibitor of metalloproteinases and their ability to predict response to treatment. J Clin Periodontol 1996, 23, 83–91.
  14. Romero AM, Mastromatteo-Alberga P, Escalona L, Correnti M: MMP-3 and MMP-8 levels in patients with chronic periodontitis before and after nonsurgical periodontal therapy. Invest Clin 2013, 54,138–148.
  15. Hernández M, Gamonal J, Tervahartiala T, Mäntylä P, Rivera O, Dezerega A, Dutzan N, Sorsa T: Associations between matrix metalloproteinase-8 and -14 and myeloperoxidase in gingival crevicular fluid from subjects with progressive chronic periodontitis: a longitudinal study. J Periodontol 2010, 81,1644–1652.
  16. Kamma JJ, Giannopoulou C, Vasdekis VG, Mombelli A: Cytokine profile in gingival crevicular fluid of aggressive periodontitis: influence of smoking and stress. J Clin Periodontol 2004, 31, 894–902.
  17. Genco RJ: Host responses in periodontal diseases: current concepts. J Periodontol 1992, 63, 338–355.
  18. Choy EHS, Panayi GS: Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001, 344, 907–916.
  19. Hanemaaijer R, Sorsa T, Konttinen YT: Matrix metalloproteinase-8 is expressed in rheumatoid synovial fibroblasts and endothelial cells. Regulation by tumor necrosis factor-alpha and doxycycline. J Biol Chem 1997, 272, 31504–31509.
  20. Howell TH, Williams RC: Nonsteroidal anti-inflammatory drugs as inhibitors of periodontal disease progression. Crit Rev Oral Biol Med 1993, 4, 177–196.
  21. Offenbacher S, Braswell LD, Loos AS: Effects of flurbiprofen on the progression of periodontitis in Macaca mulatta. J Periodontal Res 1987, 22, 473–481.
  22. Penglis PS, James MJ, Cleland LG: Cyclooxygenase inhibitors: any reservations? Review. Intern Med 2001, 31, 37–41.
  23. Silness J, Löe H: Periodontal disease in pregnancy. II. Correlation between oral hygiene and oral condition. Acta Odontol Scand 1964, 22, 121–135.
  24. Löe H: The gingival index, plaque index, and the retention index systems. J Periodontol 1967, 38, 610–616.
  25. Nowicki D, Vogel RI, Mekers S, Deasy MJ: The gingival bleeding time index. J Periodontol 1981, 52, 260–262.
  26. Kiili M, Cox SW, Chen HY: Collagenase-2(MMP-8) and collagenase-3(MMP-13) in adult periodontitis: Molecular forms and levels in gingival crevicular fluid and immunolocalisation in gingival tissue. J Clin Periodontol 2002, 29, 224–232.
  27. Griffiths GS, Curtis MA, Wilton JM: Selection of a paper with optimum properties for the collection of gingival crevicular fluid. J Periodontal Res 1988, 23, 33–38.
  28. Miller DR, Lamster IB, Chasens AI: Role of the polymorphonuclear leukocyte in periodontal health and disease. J Clin Periodontol 1984, 11, 1–15.
  29. Offenbacher S, Odle BM, Green MD: Inhibition of human periodontal prostaglandin E2 synthesis with selected agents. Agents Actions 1990, 29, 232–238.
  30. Williams RC, Jeffcoat MK, Wechter WJ, Johnson HG, Kaplan ML, Goldhaber P: Non-steroidal anti-inflammatory drug treatment of periodontitis in beagles. J Periodontal Res 1984, 19, 633–637.
  31. Shelling SH, Wolfe HJ, Jr. Tashijian AH: Role of the osteoclast in prostaglandin E2 stimulated bone resorption. Lab Invest 1980, 42, 290–295.
  32. Pelletier JP, Pelletier JM: Effects of nimesulide and naproxen on the degradation and metalloproteinase synthesis of human osteoarthritic cartilage. Drugs 1993, 1, 34–39.
  33. Salmon JA, Simmons PM, Moncada S: The effects of BW755C and other anti-inflammatory drugs on eicosanoid concentrations and leukocyte accumulation in experimentally-induced acute inflammation. J Pharm Pharmacol 1983, 35, 808–813.
  34. Kurtis B, Tüter G, Serdar M, Pınar S, Demirel I, Toyman U: GCF MMP-8 levels in smokers and non-smokers with chronic periodontitis following scaling and root planning accompanied by systemic use of flurbiprofen. J Periodontol 2007, 78, 1954–1961.
  35. Vogel RI, Copper SA, Schneider LG, Goteiner D: The effects of topical steroidal and systemic non-steroidal antiinflammatory drugs on experimental gingivitis in man. J Periodontol 1984, 55, 247–251.
  36. Johnson RH, Armitage GC, Francisco C, Page RC: Assesment of the efficacy of a non-steroidal anti-inflammatory drug, naprosyn, in treatment of gingivitis. J Periodont Res 1990, 25, 230–235.
  37. Heasman PA, Seymour RA: An association between long term non-steroidal anti-inflammatory drug therapy and the severity of periodontal disease. J Clin Periodontol 1990, 17, 654–658.
  38. Lee HM, Ciancio SG, Tüter G, Ryan ME, Komaroff E, Golup LM: Subantimicrobial dose doxycycline efficacy as a matrix metalloproteinase inhibitor in chronic periodontitis parients is enhanced when combined with a nonsteroidal anti-inflammatory drug. J Periodontol 2004, 75, 453–463.
  39. Lee W, Aitken S, Sodek JA, McCulloch C: Evidence of a direct relationship between neutrophil collagenase activity and periodontal tissue destruction in vivo: role of active enzymes in human periodontitis. J Periodont Res 1995, 30, 23–33.
  40. Romanelli R, Mancini S, Laschinger C, Overall CM, Sodek J, McCulloch CA: Activation of neutrophil collagenase in periodontitis. Infect Immun 1999, 67, 2319–2326.
  41. Mancini S, Romanelli R, Laschinger CA, Overall CM, Sodek J, McCulloch CA: Assessment of a novel screening test for neutrophil collagenase activity in the diagnosis of periodontal diseases. J Periodontol 1999, 70, 1292– –1302.
  42. Marcaccini AM, Meschiari CA, Zuardi LR, de Sousa TS, Taba M Jr, Teofilo JM, Jacob-Ferreira AL, TanusSantos JE, Novaes AB Jr, Gerlach RF: Gingival crevicular fluid levels of MMP-8, MMP-9, TIMP-2, and MPO decrease after periodontal therapy. J Clin Periodontol 2010, 37, 180–190.
  43. Kuula H, Salo T, Pirilä E, Tuomainen AM, Jauhiainen M, Uitto VJ: Local and systemic responses in matrix metalloproteinase 8-deficient mice during Porphyromonas gingivalis-induced periodontitis. Infect Immun 2009, 2, 850–859.
  44. Kinane DF, Darby IB, Said S: Changes in gingival crevicular fluid matrix metalloproteinase-8 levels during periodontal treatment and maintenance. J Periodont Res 2003, 38, 400–404.
  45. Inaba T, Ishikawa S, Miyoshi M, Kurahara K: Present status of gastrointestinal damage due to non-steroidal antiinflammatory drugs (NSAIDs). Nihon Rinsho 2013, 71, 1109–1115.
  46. Barracchini A, Franceschini N, Minisola G: Meloxicam and indomethacin activity on human matrix metalloproteinases in synovial fluid. Ann N Y Acad Sci 1999, 878, 665–666.
  47. Williams RC, Jeffcoat MK, Howell TH: Altering the progression of alveolar bone loss with the non-steroidal antiinflammatory drug flurbiprofen. J Periodontol 1989, 60, 485–490.
  48. Leppilahti JM, Ahonen MM, Hernández M: Oral rinse MMP-8 point-of-care immuno test identifies patients with strong periodontal inflammatory burden. Oral Dis 2011,17, 115–122.
  49. Sorsa T, Mäntylä P, Tervahartiala T, Pussinen PJ, Gamonal J, Hernandez M: MMP activation in diagnostics of periodontitis and systemic inflammation. J Clin Periodontol 2011, 38, 817–819.
  50. Smith MA, Braswell LD, Collins JG: Changes in inflammatory mediators in experimental periodontitis in the rhesus monkey. Infect Immun 1993, 61, 1453–1459.
  51. Stashenko P, Jandinski JJ, Fujiyoshi P, Rynar J, Socranski SS: Tissue levels of bone resorptive cytokines in periodontal disease. J Periodontol 1991, 62, 504–509.
  52. Rossomando EF, Kennedy JE, Hadjımichael J: Tumor necrosis factor alpha in gingival crevicular fluid as a possible indicator of periodontal disease in humans. Arch Oral Biol 1990, 35, 431–434.
  53. Lee HJ, Kang IK, Chung CP, Choi SM: The subgingival microflora and gingival crevicular fluid cytokines in refractory periodontitis. J Clin Periodontol 1995, 22, 885–890.
  54. Erdemir EO, Duran I, Haliloğlu S: Effects of smoking on clinical parameters and the gingival crevicular fluid levels of IL-6 and TNF-α in patients with chronic periodontitis. J Clin Periodontol 2004, 31, 99–104.
  55. Kececi A: Determining the TNFα levels in GCF of patients with adult periodontitis and the effect of NSAIDs. Dissertation 1998, University of Gazi.
© Wroclaw Medical University